Pharma & Biotech collaborations with academic institutions can result in successful relationships that produce important innovations. They also pose interesting cultural challenges that come from different approaches to communication, freedom to publish, and IP ownership. Academic institutions want research funding and measure success by original publications. Their industry partners want to find ways to bring innovative therapies to market. These differing goals can surface as points of conflict during the course of the partnership. Our panel will offer ways to help industry-academic alliances thrive.
We will explore how to:
- Establish and agree on research plans
- Manage IP with one or more institutions, handle invention disclosures, work with students and post-docs
- Govern the research collaboration; steering committees, dedicated alliance managers, budgets, invention disclosures, publication review
- Resolve conflicts
- Negotiate third-party agreements
- Measure success (leading and lagging indicators)
Jeremy Ahouse, CSAP, PhD
Executive Director, Business Development & Global Alliances
Jeremy Ahouse, CSAP, PhD — Executive Director Business Development and Global Alliances for Celgene. Jeremy is the alliance lead for a number of research and development alliances across Celgene's portfolio. He joined Celgene in 2015 after alliance roles with Novartis, ImmunoGen, Vantage and Millennium. He started working in biotech and pharma in 1999 after completing a PhD in cellular immunology and a post-doc in developmental genetics. He has served ASAP as a board member and chair of the committee that prepares the CSAP and CAAM certification exams. He has a strong interest in multi-party agreements and in the ways that collaborations enhance scientific creativity.
Christine JOST, PhD
Director, R&D Alliance Management
Christine Jost is Director, R&D Alliance Management at Sanofi. At Sanofi, Christine handles multiple academic and biotech alliances and participated in setting up the multi-institutional Sanofi iAwards. Prior to joining Sanofi in 2015, Christine was the Associate Director of the Technology Ventures Office (TVO) of Beth Israel Deaconess Medical Center (BIDMC) for 16 years. Christine holds a PhD in Molecular Biology and Genetics.
Rekha K. Paleyanda, PhD
Director, Office of Technology Commercialization
University of Massachusetts
Rekha Paleyanda is the Director of the Office of Technology Commercialization at U. Mass Lowell. She has extensive experience in identifying new product opportunities, negotiating licenses with startups and established companies, as well as managing strategic alliances with industry partners. She comes to UML after ten years in technology licensing, management and development of academic-industry alliances at Partners Healthcare, Boston. Prior to that Rekha led strategic and business development at a startup and worked in R&D developing therapeutics for orphan diseases. She received a Ph.D. from the George Washington University in Washington D.C. and conducted postdoctoral research at the Holland Lab for Biomedical Sciences in Rockville, Maryland.
Prakash Purohit PhD, MBA
Raaya Biopharma Consulting | Global Partnering, Business Strategy, Alliance Management
Prakash Purohit is currently Managing Partner, Raaya Biopharma Consulting. Prakash has over 15 years of experience in the biopharma industry both in diagnostics and pharmaceuticals discovery and development. Most recently, Prakash was Director, Scientific Affairs at Ipsen a specialty pharmaceutical company where he was responsible for scientific affairs in US/NA region. Prakash was responsible for identifying strategic partnership opportunities, negotiate and establish collaboration and manage the alliances in pre-clinical drug discovery and development. Prior joining Ipsen in 2006, Prakash was a scientific leader developing molecular assays at Millipore and biomeriux. Prakash holds a PhD in Biology and an MBA in Management.